Evidence map›Paper›PMID 41924392›Full record

ArticleTherapeutic advances in hematology2026

Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b.

Seug Yun Yoon, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Seug Yun YoonDivision of Hematology and Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0001-8228-0218
Sung-Soo YoonCancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Deok-Hwan YangDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanam-do, Korea.
Gyeong-Won LeeDivision of Hematology-Oncology, Department of Internal Medicine, Institute of Health Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.
Sang Kyun SohnDepartment of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea.
Ho-Jin ShinDepartment of Hematology/Oncology, Pusan National University Hospital, Busan, Korea.
Sung Hwa BaeDivision of Hematology/Oncology, Department of Internal Medicine, Daegu Catholic, University Hospital, Daegu Catholic University School of Medicine, Daegu, Korea.
Chul Won ChoiDivision of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
Eun-Ji ChoiDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
June-Won CheongDivision of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Soo-Mee BangDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Joon Seong ParkDepartments of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
Yong ParkDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Young Hoon ParkDivision of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea.
Sung-Eun LeeDepartment of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea.ORCID https://orcid.org/0000-0002-9810-2050

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Polycythemia vera (PV) is a myeloproliferative neoplasm driven by Objectives: To evaluate whether a ⩾50% reduction in the neutrophil-to-lymphocyte ratio (NLR) can serve as a surrogate marker of hematologic and molecular response during ropeginterferon therapy. Design: Secondary analysis of a multicenter, phase II, open-label trial in South Korea. Methods: Ninety-five patients with PV received ropeginterferon alfa-2b biweekly for 48 weeks. NLR and Results: NLR half reduction significantly predicted hematologic response (week 24 OR 6.42, Conclusion: NLR half reduction is a simple, cost-effective biomarker that may reflect molecular response and treatment efficacy in PV.

Indexed as

molecular responseneutrophil-to-lymphocyte ratiopolycythemia veraropeginterferon alfa-2b

Identifiers

PMID41924392
PMCPMC13036332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.